Two patients with chronic motor neuropathy, high antiganglioside antibody (AGA) titers, and a declining response to IV immunoglobulins were treated with rituximab at a standard dose. The drug was well tolerated and effectively eliminated peripheral B cells (CD20+), but AGA titers continued significantly high. No clinical improvement was detected during the 1-year follow-up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/01.wnl.0000098996.02934.86 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of cross-neutralizing immunity following COVID-19 primary series vaccination during the Omicron surge in Tanzania.
J Med Virol
August 2024
Campus College of Medicine, Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
COVID-19 vaccine became available in Tanzania during the first wave of the Omicron variant. During that time community seroprevalence of SARS-CoV-2 was already at 50%-80%. To date, it remains largely unknown whether ongoing vaccination with the primary series vaccines has any meaningful immune-boosting effects against newer Omicron subvariants.
View Article and Find Full Text PDFAntigliadin antibodies and the brain in people without celiac disease: a case-control study.
Am J Gastroenterol
July 2024
School of Medicine and Population Health, University of Sheffield.
Background: Anti-gliadin antibodies (AGA) occur in approximately 10% of the general population, produced as a response to gluten. Autoimmune gluten-related disorders can have detrimental neurological effects if not properly controlled but the relevance of such "incidental" AGA is not properly established; any harm caused would indicate the gluten-free diet as a means for affected people to protect their brain health. We explored this question by comparing brain MRI scanning, cognitive testing and other measures between healthy volunteers with and without AGA.
View Article and Find Full Text PDFObjectives: Typhoid remains a persistent contributor to childhood morbidity in communities lacking sanitation infrastructure. Typhoid conjugate vaccine (TCV) is effective in reducing disease risk in vaccinees; however, the duration of protection is unknown. This study measured the longevity of immune response to TCV in children aged under 10 years in Hyderabad, Pakistan, where an outbreak of extensively drug-resistant typhoid has been ongoing.
View Article and Find Full Text PDFMultiple lung abscesses and cold agglutinin syndrome following coronavirus disease 2019: a case report.
J Med Case Rep
July 2024
Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, 1-1, Mitsuzawa Nishi Machi, Kanagawa Ku, Yokohama Shi, Kanagawa Ken, 221-0855, Japan.
Article Synopsis
- - Cold agglutination syndrome is an autoimmune hemolytic anemia that causes red blood cells to clump and break down in cold temperatures, and it can be categorized into primary (occurring on its own) and secondary (occurring due to underlying infections like COVID-19).
- - A case study discusses a 69-year-old Japanese woman with periodontitis who suffered from brown urine and chest pain, revealing severe anemia linked to cold agglutination syndrome and multiple lung abscesses after her COVID-19 vaccination.
- - The findings suggest that COVID-19 can lead to secondary cold agglutination syndrome, which may worsen due to bacterial infections in the bloodstream, indicating a potential risk for patients recovering from
Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study.
Vaccine
September 2024
Department of Paediatrics and Child Health, Aga Khan University Hospital, Stadium Rd, PO Box 3500, Karachi 74800, Pakistan. Electronic address:
Background: This study aimed to assess the longevity of serologic response and seroconversion rates at several time points following TCV vaccination among children living with HIV aged 6 months to 15 years in Pakistan.
Methods: From November 20, 2020, to January 2, 2021; 336 children were enrolled and followed up prospectively for 12 months. Blood samples were collected before the administration of TCV and at 4-6 weeks, 6 months, and 1 year after administration of a single dose (0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!